Galmed Pharmaceuticals (NASDAQ:GLMD) Announces Earnings Results, Beats Expectations By $1.43 EPS

Galmed Pharmaceuticals (NASDAQ:GLMD) released its earnings results on Wednesday. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of ($0.51) by $1.43, FiscalAI reports.

Galmed Pharmaceuticals Trading Up 1.9%

NASDAQ:GLMD opened at $0.54 on Friday. The stock has a market capitalization of $2.96 million, a PE ratio of -1.69 and a beta of 0.47. Galmed Pharmaceuticals has a 1-year low of $0.41 and a 1-year high of $2.68. The firm has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.96.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 3.05% of Galmed Pharmaceuticals as of its most recent filing with the SEC. 76.14% of the stock is currently owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.